Pulmonary Arterial Hypertension — Group 1: What the Primary Care Nurse Practitioner Needs to Know (Webinar #2)

Register Now for AANP's Second Free, Live Webinar on Rare Disease: Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension webinar

May 7, 2021 5:00pm – 6:00pm (ET) Online

CE: 1.25 contact hours (CH) of continuing education (CE)
0.5 of which may be applied toward pharmacology.

Register now for this free, live webinar, presented by the American Association of Nurse Practitioners® (AANP), for an in-depth look at pulmonary arterial hypertension. Expert nurse practitioner (NP) faculty will describe the disease pathology and provide you with the tools you need to identify symptoms and evidence-based measures to ensure accurate diagnosis and management of the disease. You'll also gain strategies to identify when patients with pulmonary arterial hypertension should be referred to Pulmonary Hypertension Care Centers. Please note: On-demand viewing will not be offered for this activity. In addition, this is a repeat offering of the live webinar from April 22; if you completed the entire activity for credit on that date, you are not eligible to claim credit again for this event.

Event Details
  • Webinar Details

    Pulmonary Arterial Hypertension — Group 1: What the Primary Care Nurse Practitioner Needs to Know (Webinar #2)

    When: May 7, 2021, 5-6 p.m. ET (4-5 p.m. CT).

    Where: Online via the AANP CE Center.

    Cost: Free.

    CE credit: This activity is approved for 1.25 contact hour(s) of CE, which includes 0.5 hour(s) of pharmacology, by the American Association of Nurse Practitioners. Activity ID# 21034829. This activity was planned in accordance with AANP Accreditation Standards and Policies.

    Register Today


    About the Webinar

    Pulmonary arterial hypertension (PAH) is a type of pulmonary hypertension (PH), which generally refers to high blood pressure of the arteries of the lungs and may be caused by a variety of conditions. While considered an uncommon condition, if PAH is not treated early, it is associated with worsening symptoms, significant morbidity and a five-year survival rate of approximately 40% to 60%. Major challenges in the care of patients with PAH include delayed diagnosis, delayed initiation of appropriate treatment, delayed referral to PAH specialty centers and underutilization of evidence-based treatment recommendations.

    In this educational webinar, you can listen to two expert PAH nurse practitioners (NPs) as they explain why NPs in primary care have such a crucial role in the management of patients with this complex disease. On-demand viewing will not be offered after the conclusion of this live CE webinar.

    Please note: If you completed and received CE credit for the first offering of this webinar, which took place on April 22, 2021, you are not eligible to claim CE credit again for this event.

    This CE activity is supported by an educational grant from Actelion Pharmaceuticals, US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.


    Webinar Objectives

    • Describe the disease pathology associated with Group 1 PAH.
    • Identify symptoms associated with PAH.
    • List evidence-based measures used to establish a diagnosis of PAH.
    • Identify when patients with PAH should be referred to PH Care Centers.
    • Describe current evidence-based strategies used to manage PAH.

    Register Today

  • Speakers

    Webinar Faculty

    Dr. Kingman

    Martha Kingman, FNP, DNP

    Martha Kingman, is a family nurse practitioner (FNP) who has been working in the Pulmonary Hypertension Program, a comprehensive care center, at the University of Texas Southwestern Medical Center at Dallas since 2000. She earned a Doctorate in Nursing Practice (DNP) from Texas Christian University in 2011. Dr. Kingman serves on various PH advisory boards and steering committees; has spoken at local, national and international conferences; and is a sub-investigator in several ongoing PH clinical trials. She is an active member of the PH Professional Network and is past Chair of the symposium planning committee. Dr. Kingman has numerous PH publications and served on the Editorial Board of the Advances in Pulmonary Hypertension: Official Journal of the Pulmonary Hypertension Association. Her main area of interest involves the management of prostacyclin therapies.

    Ms. McDevitt

    Susanne E. McDevitt, MSN, ACNP-BC

    Susanne E. McDevitt is an acute care nurse practitioner (ACNP) in the Pulmonary Hypertension Program, Division of Cardiovascular Medicine, at the University of Michigan Health System. She earned a Master of Science in Nursing at Duke University, an Acute Care Nurse Practitioner certification at the University of Michigan and is currently enrolled in the DNP program at the Duke University School of Nursing. Ms. McDevitt provides comprehensive care to both inpatients and outpatients for the Pulmonary Hypertension Program, and she leads efforts in ongoing quality improvement and database research projects. She also serves on the Pulmonary Hypertension Professional Network (PHPN) Executive Committee for the Pulmonary Hypertension Association, including in her current role as PHPN 2021 Symposium Chair. She has numerous publications, has spoken at local and national conferences and is a sub-investigator for multiple PH clinical trials. She is an active member of the American Thoracic Society and the International Society of Heart and Lung Transplantation and serves on the Board of Directors for her local chapter of Sigma Theta Tau.


    Speaker Disclosures

    Martha Kingman, FNP-C, DNP, discloses relationships with the following companies:

    • Actelion Pharmaceuticals, US, Inc., Janssen Pharmaceutical Company of Johnson & Johnson: Honoraria and speakers bureau for PH.
    • Bayer: Speakers bureau for PH.
    • United Therapeutics: speakers’ bureau for pulmonary hypertension.

    Susanne E. McDevitt, MSN, ACNP-BC, has received consulting fees for PH from the following companies:

    • Acceleron Pharma.
    • Bayer.
    • Janssen.
    • United Therapeutics.

    Register Today